

The image features a hand holding a diagram of skin cells. A purple semi-transparent overlay covers the top and right portions of the image. On the right side, a diagram shows a cell signaling pathway: a purple sphere at the top has a downward arrow pointing to a cell membrane. From the membrane, two arrows point to a cell containing a nucleus. One arrow points to a small purple sphere, and the other points to a larger black sphere. The background consists of a grid of white dots on a light purple background, with a darker purple band across the middle.

EXPLORING **JAK INHIBITORS** FOR  
INFLAMMATORY SKIN DISORDERS:  
IMPROVING OUTCOMES FOR  
**ATOPIC DERMATITIS**

# Exploring JAK Inhibitors for Inflammatory Skin Disorders: Improving Outcomes for Atopic Dermatitis

## **Brett King, MD, PhD**

Associate Professor of Dermatology  
Yale University School of Medicine  
New Haven, CT

## **Sharna Givans, DNP, APRN, FNP-BC**

Tampa, FL

## **Douglas DiRuggiero, DMSc, PA-C**

Skin Cancer and Cosmetic Dermatology Center  
Rome, GA



**This program is jointly provided by AKH Inc., Advancing Knowledge in Healthcare and Catalyst Medical Education, LLC.**

### **ACTIVITY OVERVIEW**

Atopic dermatitis (AD) is an increasingly prevalent chronic systemic inflammatory disease, with significant and often underappreciated impacts on quality of life. Patients with more severe forms of AD tend to not respond to first-line therapies and traditional systemic second-line treatments can cause significant adverse effects that preclude their long-term use. An improved understanding of disease etiology has led to the development of new therapies that target pathological pathways involved in AD, including the Janus kinase (JAK)/signal transducer and activator of transcription (STAT) signaling pathway. This webinar will review the clinical manifestations and assessment of AD and provide a practical approach to AD treatment with the newer targeted agents, particularly in individuals with more severe AD, for whom other systemic and non-targeted therapies are not effective. This program has been developed for US dermatology allied healthcare professionals (HCPs) and will include several interactive case study discussions.

### **TARGET AUDIENCE**

This initiative is intended for US dermatology allied HCPs, including physician assistants, nurse practitioners, and nurses, as well as other allied HCPs who may be involved in the management of patients with AD.

### **COMMERCIAL SUPPORT**

This activity is supported by an educational grant from Pfizer, Inc.

# Learning Objectives

Upon completion of this activity, participants should be better able to:

- **Describe** the burden of AD, including clinical manifestations, associated disorders, and psychosocial impact
- **Describe** the epidemiology of AD and disease risk factors
- **Describe** the role of specific immunological pathways, such as JAK/STAT, in the pathogenesis of AD
- **Differentiate** the mechanisms of action of emerging systemic therapies for AD, including JAK inhibitors
- **Evaluate** the benefits and risks of JAK inhibitors and other emerging therapy classes in AD
- **Discuss** clinical considerations associated with the potential implementation of emerging AD therapies into practice

# Agenda

- Introduction
- **Burden of AD: Not Just Superficial**
- **Targeting the Pathophysiology of AD**
- **Benefits/Risks of Emerging Systemic Therapies for AD**
- Q&A

## CRITERIA FOR SUCCESS

Statements of credit will be awarded based on the participant's attendance, participation in the pre/post-test and submission of the activity evaluation form. A statement of credit will be available upon completion of an online evaluation. You must participate in the entire activity to receive credit. There is no fee to participate in this activity. If you have questions about this activity, please contact AKH Inc. at [tbrignoni@akhcme.com](mailto:tbrignoni@akhcme.com).



Credit provided by AKH Inc., Advancing Knowledge in Healthcare



In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and Catalyst Medical Education, LLC. AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

### Physicians

AKH Inc., Advancing Knowledge in Healthcare designates this live activity for a maximum of 1.5 *AMA PRA Category 1 Credit*<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

### Physician Assistants


AKH Inc., Advancing Knowledge in Healthcare has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.



### Nurses

1.5 ANCC contact hours.

### Nurse Practitioners

 **AANP** American Association of Nurse Practitioners This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of AKH Inc., Advancing Knowledge in Healthcare and Catalyst Medical Education, LLC. AKH Inc., Advancing Knowledge in Healthcare is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 030803. This activity is approved for 1.5 contact hour(s) (which includes 0.5 hour(s) of pharmacology).



### Disclaimer

This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content.

### Disclosure of Unlabeled Use and Investigational Product

This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

### Disclosure

It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.

### Staff/Reviewers

**Mary Gabb, MS, Medical Writer**, has no financial relationships to disclose.

**Dorothy Caputo, MA, BSN, RN, AKH CE Director of Accreditations**, has disclosed no financial relationships.

**Michele Bielarski, RN, Nurse Reviewer**, has disclosed no financial relationships.

**Bernadette Makar, MSN, APRN-BC, NP-C, Planner and Reviewer**, has disclosed no financial relationships.

**Trish Brignoni, AKH Director of Operations**, has disclosed no financial relationships.

**AKH and Catalyst Medical Education, LLC Planners and Reviewers**, have disclosed no financial relationships.

# Faculty Disclosures

**Brett King, MD, PhD, (Course Director)**, has disclosed the following relevant financial relationships:

**Consultant** - Abbvie, AltruBio Inc, Almirall, AnaptysBio, Arena Pharmaceuticals, Bioniz Therapeutics, Bristol-Meyers Squibb, Concert Pharmaceuticals Inc, Equillium, Horizon Therapeutics, Eli Lilly and Company, Incyte Corp, Janssen Pharmaceuticals, LEO Pharma, Otsuka/Visterra Inc, Pfizer Inc, Regeneron, Sanofi Genzyme, TWi Biotechnology Inc, and Viela Bio

**Research** - AnaptysBio, Arena Pharmaceuticals, Concert Pharmaceuticals Inc, Eli Lilly and Company, Pfizer Inc

**Speaker** - Abbvie, Eli Lilly, Incyte, Pfizer Inc, Regeneron and Sanofi Genzyme

**Sharna Givans, DNP, APRN, FNP-BC**, has disclosed no financial relationships.

**Douglas DiRuggiero, DMSc, PA-C**, has disclosed no financial relationships.